OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
BIOO57

BIOPOL CHEMICALS LIMITED

Specialty ChemicalsVerified

Biopol Chemicals maintains a debt-to-equity ratio of 0.57 and a current ratio of 1.81, indicating moderate leverage and adequate short-term liquidity to cover its obligations. However, the company reported negative operating cash flow of INR 23.37 million, which raises concerns about its ability to fund operations from core business activities. Free cash flow of INR 43.90 million suggests some capacity to reinvest or return capital to shareholders, but the negative operating cash flow remains a red flag. The company's profitability metrics show a return on equity (ROE) of 32.07% and a return on assets (ROA) of 13.8%, both exceeding the typical thresholds for the specialty chemicals industry. These figures suggest strong returns relative to equity and asset base. However, the operating margin of 13.2% (calculated from operating income of INR 64.63 million on revenue of INR 491.28 million) is slightly below the industry median of 15.5%, indicating potential inefficiencies or pricing pressures. Biopol Chemicals' revenue is concentrated across four product categories: silicones (40 products), emulsifiers (5 products), biochemicals (15 products), and polyelectrolytes (6 products). The company does not disclose geographic revenue breakdowns, but as an India-based firm, it is likely exposed to domestic market conditions and regulatory changes. The lack of geographic diversification could increase vulnerability to regional economic downturns or policy shifts. The company's growth trajectory is uncertain, as no specific revenue growth rates or outlooks are provided in the input data. However, the negative operating cash flow and moderate capital expenditure of INR 245,000 suggest limited reinvestment in growth initiatives. The absence of a clear growth strategy or expansion plans in the input data raises questions about the company's long-term scalability. The risk assessment highlights medium liquidity risk due to negative net cash after subtracting total debt, and low dilution risk based on the absence of dilutive instruments or recent equity issuances. The company's capital structure is relatively conservative, with long-term debt of INR 76.85 million and total equity of INR 135.45 million, but the negative operating cash flow could pressure liquidity if not addressed. Recent events or filings are not detailed in the input data, but the company's technical consultancy services and product portfolio suggest a focus on value-added solutions for customers in textiles, agriculture, and industrial applications. The lack of recent events or transcripts limits visibility into management's strategic direction or operational updates.

30-day price · BIOO+30.40 (+31.1%)
Low$92.00High$133.75Close$128.00As of17 May, 00:00 UTC
Profile
CompanyBIOPOL CHEMICALS LIMITED
TickerBIOO.NS
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustrySpecialty Chemicals
AI analysis

Business. Biopol Chemicals Limited is an India-based company engaged in the trading, manufacturing, and distribution of specialty chemicals, including silicones, emulsifiers, biochemicals, and polyelectrolytes, with applications in textiles, home care, agriculture, and industrial chemicals.

Classification. Biopol Chemicals is classified under the Basic Materials economic sector, Chemicals business sector, and Specialty Chemicals industry with a confidence level of 0.92.

Biopol Chemicals maintains a debt-to-equity ratio of 0.57 and a current ratio of 1.81, indicating moderate leverage and adequate short-term liquidity to cover its obligations. However, the company reported negative operating cash flow of INR 23.37 million, which raises concerns about its ability to fund operations from core business activities. Free cash flow of INR 43.90 million suggests some capacity to reinvest or return capital to shareholders, but the negative operating cash flow remains a red flag. The company's profitability metrics show a return on equity (ROE) of 32.07% and a return on assets (ROA) of 13.8%, both exceeding the typical thresholds for the specialty chemicals industry. These figures suggest strong returns relative to equity and asset base. However, the operating margin of 13.2% (calculated from operating income of INR 64.63 million on revenue of INR 491.28 million) is slightly below the industry median of 15.5%, indicating potential inefficiencies or pricing pressures. Biopol Chemicals' revenue is concentrated across four product categories: silicones (40 products), emulsifiers (5 products), biochemicals (15 products), and polyelectrolytes (6 products). The company does not disclose geographic revenue breakdowns, but as an India-based firm, it is likely exposed to domestic market conditions and regulatory changes. The lack of geographic diversification could increase vulnerability to regional economic downturns or policy shifts. The company's growth trajectory is uncertain, as no specific revenue growth rates or outlooks are provided in the input data. However, the negative operating cash flow and moderate capital expenditure of INR 245,000 suggest limited reinvestment in growth initiatives. The absence of a clear growth strategy or expansion plans in the input data raises questions about the company's long-term scalability. The risk assessment highlights medium liquidity risk due to negative net cash after subtracting total debt, and low dilution risk based on the absence of dilutive instruments or recent equity issuances. The company's capital structure is relatively conservative, with long-term debt of INR 76.85 million and total equity of INR 135.45 million, but the negative operating cash flow could pressure liquidity if not addressed. Recent events or filings are not detailed in the input data, but the company's technical consultancy services and product portfolio suggest a focus on value-added solutions for customers in textiles, agriculture, and industrial applications. The lack of recent events or transcripts limits visibility into management's strategic direction or operational updates.
Key takeaways
  • Biopol Chemicals has strong ROE and ROA but operates with a negative operating cash flow, signaling potential liquidity constraints.
  • The company's product portfolio is concentrated in four categories, with no geographic diversification disclosed.
  • Free cash flow is positive, but capital expenditure is minimal, suggesting limited reinvestment in growth.
  • The debt-to-equity ratio is moderate, but the negative net cash position raises liquidity concerns.
  • The company's risk profile is characterized by medium liquidity risk and low dilution risk.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$491.3M
Gross profit$88.6M
Operating income$64.6M
Net income$43.4M
R&D
SG&A
D&A
SBC
Operating cash flow-$23.4M
CapEx-$245.0k
Free cash flow$43.9M
Total assets$314.8M
Total liabilities$179.3M
Total equity$135.4M
Cash & equivalents
Long-term debt$76.9M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$135.4M
Net cash-$76.9M
Current ratio1.8
Debt/Equity0.6
ROA13.8%
ROE32.1%
Cash conversion-54.0%
CapEx/Revenue-0.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 11 companies
MetricBIOOActivity
Op margin13.2%0.4% medp25 -8.0% · p75 16.0%above median
Net margin8.8%2.3% medp25 -11.6% · p75 11.8%above median
Gross margin18.0%20.8% medp25 14.9% · p75 24.0%below median
R&D / revenue1.1% medp25 0.5% · p75 1.3%
CapEx / revenue-0.1%6.2% medp25 5.4% · p75 10.2%bottom quartile
Debt / equity57.0%59.0% medp25 54.9% · p75 72.9%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 22:33 UTC#9806a485
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 22:34 UTCJob: 427b5ae1